Evaxion Biotech A/S
Evaxion Biotech A/S (EVAX) Revenue
Annual & quarterly revenue history · segment & region breakdown
EVAX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsEvaxion Biotech A/S trailing twelve-month (TTM) revenue is $0.01B, an increase of 125.12% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.00B | +125.12% |
| 2024-12-31 | $0.00B | +$0.00B | +4480.82% |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Evaxion Biotech A/S receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Evaxion Biotech A/S reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Evaxion Biotech A/S's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EVAX revenue · 4 questionsEVAX's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 125.12% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Evaxion Biotech A/S SEC filings · GAAP · Evaxion Biotech A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026